Dr. Reddys Laboratories Ltd.

Dr. Reddys Laboratories is currently trading at Rs. 4871.60, up by 107.65 points or 2.26% from its previous closing of Rs. 4763.95 on the BSE.

The scrip opened at Rs. 4790.00 and has touched a high and low of Rs. 4902.75 and Rs. 4790.00 respectively. So far 0.52 lakh shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 5,613.65 on 07-Jul-2021 and a 52 week low of Rs. 4,135.90 on 19-Mar-2021.

Last one week high and low of the scrip stood at Rs. 4902.75 and Rs. 4488.00 respectively. The current market cap of the company is Rs. 81,144.26 crore.

The promoters holding in the company stood at 26.73%, while Institutions and Non-Institutions held 44.78% and 28.49% respectively.

Dr. Reddy's Laboratories has launched Reddy-Lenalidomide, a generic equivalent to Revlimid (lenalidomide) capsules in the Canadian market. Reddy-Lenalidomide is one of the first generic medications of its kind to launch in Canada. Reddy-Lenalidomide capsules are available in 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg strengths, each in blister packs.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.